Merck: Keytruda granted priority status for Hodgkin lymphoma
(CercleFinance.com) - Merck said that the US Food and Drug Administration has accepted its application for an expanded use of its blockbuster cancer drug Keytruda, granting it priority review.
The application is for the second-line treatment of patients with relapsed or refractory classical Hodgkin lymphoma, a type of lymphoma that develops in the white blood cells of the immune system.
Typical Hodgkin lymphoma represents over 90% of Hodgkin lymphoma cases, which affects approximately 7,400 patients a year in the US.
The FDA has set a target action date of 30 October.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The application is for the second-line treatment of patients with relapsed or refractory classical Hodgkin lymphoma, a type of lymphoma that develops in the white blood cells of the immune system.
Typical Hodgkin lymphoma represents over 90% of Hodgkin lymphoma cases, which affects approximately 7,400 patients a year in the US.
The FDA has set a target action date of 30 October.
Copyright (c) 2020 CercleFinance.com. All rights reserved.